Jessica R. Frankum
London, ENG SW36JB, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
Journal: Oncogene
Published: June 17, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 20, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer.
Journal: Nature communications
Published: May 25, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Journal: Oncogene
Published: March 03, 2023
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance.
Journal: Oncogene
Published: July 29, 2021
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.
Journal: Cancer discovery
Published: December 17, 2019
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Journal: Scientific reports
Published: March 02, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
Journal: Cell reports
Published: January 31, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Journal: Nature communications
Published: September 29, 2017
Last Updated: 09/26/2026